EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Treatment Retention and Safety of Ixekizumab in Psoriatic Arthritis: A Real Life Single-Center Experience

Ignacio Braña, Estefanía Pardo, Stefanie Burger, Pablo González Del Pozo, Mercedes Alperi, Rubén Queiro iD

Journal of Clinical Medicine · 06.01.2023 · 12 (2) · 467

DOI: 10.3390/jcm12020467 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 06.01.2023. Verfasst von Ignacio Braña und 5 weiteren Autor:innen. Beteiligte Einrichtung: Rheumatology Division, Hospital Universitario Central de Asturias (HUCA), 33011 Oviedo, Spain. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Eli Lilly.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and objectives: Information on the performance of ixekizumab (IXE) in patients with psoriatic arthritis (PsA) in clinical practice is scarce. We aimed to analyze the retention rate and safety of IXE in patients with PsA in routine clinical practice.

Methods

A retrospective longitudinal observational single-center study of all patients with PsA who had received at least one dose of IXE. Adverse events (AEs) and drug retention rate were the main study focus. Survival was analyzed using Kaplan–Meier curves and predictive factors using multivariate Cox regression analysis. The hazard ratio (HR) was used as a measure of the association.

Results

Seventy-two patients were included (52 women and 20 men). Median disease duration was 5 years (IQR 3–9). More than 90% received ≥2 biologic and/or targeted synthetic disease-modifying anti-rheumatic drugs (DMARDs) prior to IXE. Ixekizumab showed a 1-year retention rate of 65% and a 2-year retention rate of 57%. Regarding discontinuation due to AEs, 0.18 AEs per person-year were identified. The number of previous biologics did not influence drug survival but prior use of methotrexate (HR 2.31 (95% CI 1.05–5.10), p < 0.05) and depression (HR 2.40 (95% CI 1.07–5.41), p < 0.05) increased the risk of IXE discontinuation.

Conclusions

Ixekizumab showed a good retention rate in a PsA population mostly refractory to biologic and targeted synthetic DMARDs. Drug survival was consistently good regardless of age, gender, metabolic comorbidities, smoking status, or prior number of biologic therapies. This information may be of interest to better position this drug in the PsA treatment algorithms.

Schlagwörter

Stichwörter der Autor:innen

biologic therapydrug survivalixekizumabpsoriatic arthritissafety

Autor:innen und Institutionen

  • Rheumatology Division, Hospital Universitario Central de Asturias (HUCA), 33011 Oviedo, Spain.
  • ISPA Translational Immunology Division & Oviedo University School of Medicine, 33011 Oviedo, Spain.

ORCID-Profile: Rubén Queiro

Förderung

  • Eli Lilly

Zitieren

APA

Braña, I., Pardo, E., Burger, S., González Del Pozo, P., Alperi, M., & Queiro, R. (2023). Treatment Retention and Safety of Ixekizumab in Psoriatic Arthritis: A Real Life Single-Center Experience. Journal of Clinical Medicine, 12(2), 467. https://doi.org/10.3390/jcm12020467

Vancouver

Braña I, Pardo E, Burger S, González Del Pozo P, Alperi M, Queiro R. Treatment Retention and Safety of Ixekizumab in Psoriatic Arthritis: A Real Life Single-Center Experience. Journal of Clinical Medicine. 2023;12(2):467. doi:10.3390/jcm12020467

BibTeX
@article{Braa2023,
  author = {Braña, Ignacio and Pardo, Estefanía and Burger, Stefanie and González Del Pozo, Pablo and Alperi, Mercedes and Queiro, Rubén},
  title = {Treatment Retention and Safety of Ixekizumab in Psoriatic Arthritis: A Real Life Single-Center Experience},
  journal = {Journal of Clinical Medicine},
  year = {2023},
  volume = {12},
  number = {2},
  pages = {467},
  doi = {10.3390/jcm12020467}
}
Kostenlos starten →